Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

Sarah R. Verhoeff; S. Es; E. Boon; E. van Helden; L. Angus; S. Elias; S. Oosting; E. Aarntzen; A. Brouwers; S. Heskamp; O. S. Hoekstra; H. M. Verheul; A. A. M. Van der Veldt; E. G. E. de Vries; O. Boerman; W. T. A. van der Graaf; W. J. G. Oyen; C. M. L. van Herpen

doi:10.1093/annonc/mdy283.097

Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

Sarah R. Verhoeff, S. Es, E. Boon, E. van Helden, L. Angus, S. Elias, S. Oosting, E. Aarntzen, A. Brouwers, S. Heskamp, O. S. Hoekstra, H. M. Verheul, A. A. M. Van der Veldt, E. G. E. de Vries, O. Boerman, W. T. A. van der Graaf, W. J. G. Oyen, C. M. L. van Herpen

Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Article number	888P
Pages (from-to)	viii314-viii315
Number of pages	2
Journal	Annals of Oncology
Volume	29
Issue number	Suppl.8
DOIs	https://doi.org/10.1093/annonc/mdy283.097
Publication status	Published - Oct-2018
Event	43rd ESMO Congress (ESMO) - Munich, Germany Duration: 19-Oct-2018 → 23-Oct-2018

Access to Document

10.1093/annonc/mdy283.097

Handle.net

Persistent link

Embargoed Document

Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with
Final publisher's version, 96.5 KB

Cite this

Verhoeff, S. R., Es, S., Boon, E., van Helden, E., Angus, L., Elias, S., Oosting, S., Aarntzen, E., Brouwers, A., Heskamp, S., Hoekstra, O. S., Verheul, H. M., Van der Veldt, A. A. M., de Vries, E. G. E., Boerman, O., van der Graaf, W. T. A., Oyen, W. J. G., & van Herpen, C. M. L. (2018). Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology, 29(Suppl.8), viii314-viii315. Article 888P. https://doi.org/10.1093/annonc/mdy283.097

@article{902bb1bfbd8e412087c4814a7f894475,

title = "Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)",

author = "Verhoeff, {Sarah R.} and S. Es and E. Boon and {van Helden}, E. and L. Angus and S. Elias and S. Oosting and E. Aarntzen and A. Brouwers and S. Heskamp and Hoekstra, {O. S.} and Verheul, {H. M.} and {Van der Veldt}, {A. A. M.} and {de Vries}, {E. G. E.} and O. Boerman and {van der Graaf}, {W. T. A.} and Oyen, {W. J. G.} and {van Herpen}, {C. M. L.}",

year = "2018",

month = oct,

doi = "10.1093/annonc/mdy283.097",

language = "English",

volume = "29",

pages = "viii314--viii315",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Suppl.8",

note = "43rd ESMO Congress (ESMO) ; Conference date: 19-10-2018 Through 23-10-2018",

}

Verhoeff, SR, Es, S, Boon, E, van Helden, E, Angus, L, Elias, S, Oosting, S, Aarntzen, E, Brouwers, A, Heskamp, S, Hoekstra, OS, Verheul, HM, Van der Veldt, AAM, de Vries, EGE, Boerman, O, van der Graaf, WTA, Oyen, WJG & van Herpen, CML 2018, 'Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)', Annals of Oncology, vol. 29, no. Suppl.8, 888P, pp. viii314-viii315. https://doi.org/10.1093/annonc/mdy283.097

TY - JOUR

T1 - Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

AU - Verhoeff, Sarah R.

AU - Es, S.

AU - Boon, E.

AU - van Helden, E.

AU - Angus, L.

AU - Elias, S.

AU - Oosting, S.

AU - Aarntzen, E.

AU - Brouwers, A.

AU - Heskamp, S.

AU - Hoekstra, O. S.

AU - Verheul, H. M.

AU - Van der Veldt, A. A. M.

AU - de Vries, E. G. E.

AU - Boerman, O.

AU - van der Graaf, W. T. A.

AU - Oyen, W. J. G.

AU - van Herpen, C. M. L.

PY - 2018/10

Y1 - 2018/10

U2 - 10.1093/annonc/mdy283.097

DO - 10.1093/annonc/mdy283.097

M3 - Meeting Abstract

SN - 0923-7534

VL - 29

SP - viii314-viii315

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.8

M1 - 888P

T2 - 43rd ESMO Congress (ESMO)

Y2 - 19 October 2018 through 23 October 2018

ER -